Gilead Sciences (NASDAQ:GILD) has been downgraded from Outperform to Market Perform in a statement by Leerink Swann earlier today.
- Updated: September 26, 2016
Leerink Swann has downgraded Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform in a statement released on Tuesday September 27, 2016.
Boasting a price of $80.62, Gilead Sciences (NASDAQ:GILD) traded -0.91% lower on the day. With the last close down -6.12% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Gilead Sciences has recorded a 50-day average of $79.46 and a two hundred day average of $85.89. Volume of trade was down over the average, with 7,037,313 shares of GILD changing hands under the typical 10,680,600
With a total market value of $0, Gilead Sciences has price-earnings ratio of 7.08 with a one year low of $76.67 and a one year high of $111.11 .
A total of 19 analysts have released a research note on GILD. Seven analysts rating the company a strong buy, nine analysts rating the company a buy, nine analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $111.05.
More About Gilead Sciences (NASDAQ:GILD)
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.